Second generation mTOR inhibitors that act as ATP-competitive inhibitors of both mTORC1 and mTORC2, or dual specificity inhibitors that target PI3K as well, indirectly suggest a role for mTORC2 in cancer development, possibly by rendering cancer cells more sensitive to replication stress (Yu et al, 2009; Falcon et al, 2011; Guo et al, 2014). This evidence concerns the gene MTOR and cancer.